TITLE

Klemtner adds new Nexium to roster of meds

AUTHOR(S)
Goetzl, David; Linnett, Richard; Petrecca, Laura
PUB. DATE
July 2000
SOURCE
Advertising Age;7/31/2000, Vol. 71 Issue 32, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that drug company AstraZeneca chose Klemtner Advertising to handle the creative account for its heartburn treatment Nexium in the United States. Klemtner was recognized for its successful campaign for Prilosec. However, the company is still uncertain about the billings of the account until the drug enters the market after Food and Drug Administration (FDA) approval.
ACCESSION #
3382598

 

Related Articles

  • FDA Advisers Back AstraZeneca's Heart Pill.  // BioWorld Today;8/2/2010, Vol. 21 Issue 147, p6 

    The article reports on the recommendation by an advisory panel of the U.S. Food and Drug Administration (FDA) in August 2010 of the approval of AstraZeneca plc's experimental drug Brilinta to minimize thrombotic effects in patients with acute coronary syndrome.

  • AstraZeneca Gets FDA OK for Brilinta.  // Chain Drug Review;8/29/2011, Vol. 33 Issue 14, p37 

    The article reports on the approval of Brilinta, blood thinner, by the U.S. Food and Drug Administration from AstraZeneca PLC.

  • AstraZeneca's Crestor FDA Okay.  // Chemical Market Reporter;8/18/2003, Vol. 264 Issue 5, p11 

    Reports on the marketing approval for Astrazeneca PLC's anti-cholesterol drug Crestol in the U.S. Approval from the Food and Drug Administration of the drug in a 10mg once-daily dose with an available dose of range of five to 40mg; Clinical development program for Crestor; Withdrawal of Bayer's...

  • Cancer Drug Is Cleared.  // Chain Drug Review;4/25/2011, Vol. 33 Issue 8, p218 

    The article reports on the approval of AstraZeneca PLC's thyroid cancer treatment vandetanib by the U.S. Food and Drug Administration (FDA) in 2011.

  • FDA approves AstraZeneca's oncedaily version of Seroquel.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p12 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on Seroquel extended-release tablets, a once-daily treatment for schizophrenia, of AstraZeneca PLC. According to the company, the new version of Seroquel is intended to make the administration of the schizophrenia...

  • FDA Issues Complete Response for MedImmune Lung Drug. Young, Donna // BioWorld Today;12/2/2008, Vol. 19 Issue 233, p1 

    The article reports on an announcement by MedImmune Inc. and its parent company AstraZeneca plc that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for motavizumab, a monoclonal antibody from under investigation as a therapy to prevent serious respiratory...

  • Pozen Gets $10M Payday for FDA Accepting Vimovo Filing. Hollingsworth, Catherine // BioWorld Today;9/1/2009, Vol. 20 Issue 168, p1 

    The article reports on a 10 million U.S. dollars milestone payment made by AstraZeneca plc to Pozen Inc. following the U.S. Food & Drug Administration's (FDA) acceptance of its drug application for Vimovo. The drug would undergo approval for the treatment of signs and symptoms of osteoarthritis,...

  • Pozen Gets $10M Payday for Vimovo Filing.  // Bioworld Week;9/7/2009, Vol. 17 Issue 36, p3 

    The article reports on the 10 million-dollar payment acquired by Pozen Inc. from AstraZeneca PLC after the acceptance of its drug application for Vimovo by Food and Drug Administration in the U.S. It mentions that the company is aiming for the approval of its product for marketing by FDA....

  • FDA gives nod to new indication for quetiapine.  // Drug Topics;1/26/2004, Vol. 148 Issue 2, p11 

    Reports on the approval of Quetiapine from AstraZeneca PLC as monotherapy and adjunct therapy with lithium or divalproex for the short-term treatment of acute manic episodes associated with bipolar I disorder by the U.S. Food and Drug Administration.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics